O
Oliver W. Press
Researcher at Fred Hutchinson Cancer Research Center
Publications - 425
Citations - 24724
Oliver W. Press is an academic researcher from Fred Hutchinson Cancer Research Center. The author has contributed to research in topics: Radioimmunotherapy & Transplantation. The author has an hindex of 80, co-authored 424 publications receiving 23103 citations. Previous affiliations of Oliver W. Press include Group Health Research Institute & Harvard University.
Papers
More filters
Journal ArticleDOI
Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support
Oliver W. Press,Janet F. Eary,Frederick R. Appelbaum,Paul J. Martin,Christopher C. Badger,Wil B. Nelp,Stephan D. Glenn,Greg Butchko,Darrell R. Fisher,Bruce A. Porter,Dana C. Matthews,LD Fisher,Irwin D. Bernstein +12 more
TL;DR: High-dose radioimmunotherapy with 131I-labeled antibodies is associated with a high response rate in patients with B-cell lymphoma in whom antibody biodistribution is favorable.
Journal ArticleDOI
Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells.
Brian G. Till,Brian G. Till,Michael C. Jensen,Jinjuan Wang,Eric Y. Chen,Brent L. Wood,Harvey A. Greisman,Xiaojun Qian,Scott E. James,Andrew Raubitschek,Stephen J. Forman,Ajay K. Gopal,Ajay K. Gopal,John M. Pagel,John M. Pagel,Catherine G. Lindgren,Philip D. Greenberg,Philip D. Greenberg,Stanley R. Riddell,Stanley R. Riddell,Oliver W. Press,Oliver W. Press +21 more
TL;DR: The results of a proof-of-concept clinical trial in which patients with relapsed or refractory indolent B-cell lymphoma or mantle cell lymphoma were treated with autologous T cells genetically modified by electroporation with a vector plasmid encoding a CD20-specific chimeric T- cell receptor and neomycin resistance gene show the safety, feasibility, and potential antitumor activity of adoptive T-cell therapy using this approach.
Journal ArticleDOI
Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies
TL;DR: It is suggested that ligation of CD20 in vivo by anti-CD20 antibodies in the presence of FcR-expressing cells may initiate signal transduction events that induce elevation of [Ca2+]i and lead to apoptosis of malignant B cells, thereby contributing to the impressive tumor regressions observed in mouse models and clinical trials using anti- CD20 MoAbs.
Journal ArticleDOI
Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas
Mark S. Kaminski,Andrew D. Zelenetz,Oliver W. Press,Mansoor N. Saleh,John P. Leonard,L. Fehrenbacher,T. A. Lister,R. J. Stagg,George F. Tidmarsh,Stewart Kroll,Richard L. Wahl,Susan J. Knox,J. M. Vose +12 more
TL;DR: A single course of iodine I 131 tositumomab was significantly more efficacious than the LQC received by extensively pretreated patients with chemotherapy-refractory, low-grade, or transformed low- grade non-Hodgkin's lymphoma and had an acceptable safety profile.
Journal ArticleDOI
CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results.
Brian G. Till,Brian G. Till,Michael C. Jensen,Michael C. Jensen,Jinjuan Wang,Xiaojun Qian,Ajay K. Gopal,Ajay K. Gopal,David G. Maloney,David G. Maloney,Catherine G. Lindgren,Yukang Lin,John M. Pagel,John M. Pagel,Lihua E. Budde,Lihua E. Budde,Andrew Raubitschek,Stephen J. Forman,Philip D. Greenberg,Philip D. Greenberg,Stanley R. Riddell,Stanley R. Riddell,Oliver W. Press,Oliver W. Press +23 more
TL;DR: A pilot clinical trial testing a "third-generation" CD20-specific CAR with CD28 and 4-1BB costimulatory domains in patients with relapsed indolent B-cell and mantle cell lymphomas found that adoptive immunotherapy with CD 20-specific T cells was well tolerated and was associated with antitumor activity.